DENTSPLY SIRONA (NASDAQ:XRAY) Upgraded to “Hold” at BMO Capital Markets

BMO Capital Markets upgraded shares of DENTSPLY SIRONA (NASDAQ:XRAY) to a hold rating in a research report released on Wednesday,Zacks.com reports.

A number of other analysts also recently issued reports on XRAY. UBS Group dropped their price objective on shares of DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Weiss Ratings cut DENTSPLY SIRONA from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. Mizuho lowered their price target on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Citigroup assumed coverage on DENTSPLY SIRONA in a research note on Wednesday, April 15th. They set a “sell” rating and a $10.00 price target for the company. Finally, Barclays reduced their price objective on DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating on the stock in a research report on Thursday, June 4th. Three analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $13.42.

DENTSPLY SIRONA Trading Up 0.9%

Shares of XRAY opened at $11.89 on Wednesday. The firm’s 50 day simple moving average is $10.59 and its 200 day simple moving average is $11.67. The company has a market capitalization of $2.38 billion, a P/E ratio of -3.77, a P/E/G ratio of 1.40 and a beta of 0.89. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.53 and a quick ratio of 0.98. DENTSPLY SIRONA has a 1-year low of $9.40 and a 1-year high of $17.09.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). The company had revenue of $880.00 million during the quarter, compared to analysts’ expectations of $841.80 million. DENTSPLY SIRONA had a positive return on equity of 18.83% and a negative net margin of 17.06%.DENTSPLY SIRONA’s quarterly revenue was up .1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.43 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Sell-side analysts forecast that DENTSPLY SIRONA will post 1.42 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Brian T. Gladden acquired 9,985 shares of DENTSPLY SIRONA stock in a transaction dated Monday, June 15th. The shares were purchased at an average cost of $10.02 per share, with a total value of $100,049.70. Following the completion of the purchase, the director owned 61,849 shares of the company’s stock, valued at $619,726.98. This represents a 19.25% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Michael J. Barber acquired 15,175 shares of the firm’s stock in a transaction dated Thursday, June 11th. The stock was bought at an average price of $9.88 per share, for a total transaction of $149,929.00. Following the acquisition, the director owned 55,943 shares of the company’s stock, valued at approximately $552,716.84. This trade represents a 37.22% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have purchased 35,160 shares of company stock valued at $351,179. 0.46% of the stock is currently owned by insiders.

Institutional Trading of DENTSPLY SIRONA

Several hedge funds and other institutional investors have recently bought and sold shares of XRAY. First Eagle Investment Management LLC increased its stake in shares of DENTSPLY SIRONA by 3.2% in the fourth quarter. First Eagle Investment Management LLC now owns 14,640,555 shares of the medical instruments supplier’s stock worth $167,342,000 after buying an additional 458,744 shares during the period. Sound Income Strategies LLC boosted its position in DENTSPLY SIRONA by 32.3% during the 4th quarter. Sound Income Strategies LLC now owns 611,308 shares of the medical instruments supplier’s stock valued at $7,464,000 after buying an additional 149,384 shares during the period. Invenomic Capital Management LP boosted its position in DENTSPLY SIRONA by 48.7% during the 3rd quarter. Invenomic Capital Management LP now owns 4,351,199 shares of the medical instruments supplier’s stock valued at $55,217,000 after buying an additional 1,425,637 shares during the period. Crawford Investment Counsel Inc. bought a new stake in DENTSPLY SIRONA in the 3rd quarter worth $1,104,000. Finally, Great Hill Capital LLC purchased a new position in shares of DENTSPLY SIRONA in the fourth quarter valued at about $8,267,000. Institutional investors own 95.70% of the company’s stock.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.